{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:57:28Z","timestamp":1790758648066,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,29]],"date-time":"2020-12-29T00:00:00Z","timestamp":1609200000000},"content-version":"vor","delay-in-days":728,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2019]]},"DOI":"10.1136\/esmoopen-2019-000669","type":"journal-article","created":{"date-parts":[[2020,3,10]],"date-time":"2020-03-10T14:55:32Z","timestamp":1583852132000},"page":"e000669","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"S2","title":["How I treat malignant pleural mesothelioma"],"prefix":"10.1016","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4473-9387","authenticated-orcid":false,"given":"Giuseppe","family":"Viscardi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4511-7969","authenticated-orcid":false,"given":"Raimondo","family":"Di Liello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floriana","family":"Morgillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/esmoopen-2019-000669_bb0010","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/sj.bjc.6601638","article-title":"The mesothelioma epidemic in Western Europe: an update","volume":"90","author":"Pelucchi","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1136\/esmoopen-2019-000669_bb0015","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/ng.912","article-title":"Germline BAP1 mutations predispose to malignant mesothelioma","volume":"43","author":"Testa","year":"2011","journal-title":"Nat Genet"},{"key":"10.1136\/esmoopen-2019-000669_bb0020","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1097\/JTO.0b013e3182208e3f","volume":"6","author":"Rice","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1136\/esmoopen-2019-000669_bb0025","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1097\/JTO.0b013e3181ed0489","article-title":"A systematic review of extrapleural pneumonectomy for malignant pleural mesothelioma","volume":"5","author":"Cao","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1136\/esmoopen-2019-000669_bb0030","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.athoracsur.2014.09.056","article-title":"Meta-analysis of survival after pleurectomy decortication versus extrapleural pneumonectomy in mesothelioma","volume":"99","author":"Taioli","year":"2015","journal-title":"Ann Thorac Surg"},{"key":"10.1136\/esmoopen-2019-000669_bb0035","first-page":"428","article-title":"Systematic review of trimodality therapy for patients with malignant pleural mesothelioma","volume":"1","author":"Cao","year":"2012","journal-title":"Ann Cardiothorac Surg"},{"key":"10.1136\/esmoopen-2019-000669_bb0040","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1470-2045(11)70149-8","article-title":"Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the mesothelioma and radical surgery (MARs) randomised feasibility study","volume":"12","author":"Treasure","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1136\/esmoopen-2019-000669_bb0045","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2019-000669_bb0050","article-title":"Pemetrexed in combination with cisplatin versus carboplatin as first-line therapy in patients with advanced-stage malignant pleural mesothelioma (MPM): a systematic review and meta-analysis","volume":"34S","author":"Srour","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2019-000669_bb0055","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1200\/JCO.1999.17.1.25","article-title":"Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study","volume":"17","author":"Byrne","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2019-000669_bb0060","article-title":"Randomized phase 2 study of maintenance pemetrexed (Pem) versus observation (Obs) for patients (pts) with malignant pleural mesothelioma (MPM) without progression after first-line chemotherapy: cancer and leukemia group B (CALGB) 30901 (Alliance)","volume":"37S","author":"DudekAZ","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2019-000669_bb0065","doi-asserted-by":"crossref","first-page":"v931","DOI":"10.1093\/annonc\/mdz394.092","article-title":"Switch maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma: a multicenter open label phase II trial (NVALT19)","volume":"30","author":"Burgers","year":"2019","journal-title":"Annals of Oncology"},{"key":"10.1136\/esmoopen-2019-000669_bb0070","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the mesothelioma Avastin cisplatin pemetrexed study (maps): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"10.1136\/esmoopen-2019-000669_bb0075","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S2213-2600(19)30139-0","article-title":"Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"7","author":"Scagliotti","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1136\/esmoopen-2019-000669_bb0080","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/S0140-6736(14)60418-9","article-title":"Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial","volume":"384","author":"Rintoul","year":"2014","journal-title":"Lancet"},{"key":"10.1136\/esmoopen-2019-000669_bb0085","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.lungcan.2013.11.004","article-title":"Radiotherapy for the treatment of pain in malignant pleural mesothelioma: a systematic review","volume":"83","author":"Macleod","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1136\/esmoopen-2019-000669_bb0090","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1470-2045(16)30095-X","article-title":"Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (smart): a multicentre, open-label, phase 3, randomised controlled trial","volume":"17","author":"Clive","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1136\/esmoopen-2019-000669_bb0095","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.lungcan.2010.12.004","article-title":"Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma","volume":"72","author":"Ceresoli","year":"2011","journal-title":"Lung Cancer"},{"key":"10.1136\/esmoopen-2019-000669_bb0100","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.lungcan.2014.03.006","article-title":"Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma","volume":"84","author":"Zauderer","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1136\/esmoopen-2019-000669_bb0105","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2B trial","volume":"18","author":"Maio","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1136\/esmoopen-2019-000669_bb0110","doi-asserted-by":"crossref","first-page":"v931","DOI":"10.1093\/annonc\/mdz394.091","article-title":"A multicentre randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural mesothelioma (MPM): results from the European thoracic oncology platform (ETOP 9-15) PROMISE-meso trial","volume":"30","author":"Popat","year":"2019","journal-title":"Annals of Oncology"},{"key":"10.1136\/esmoopen-2019-000669_bb0115","doi-asserted-by":"crossref","first-page":"S338","DOI":"10.1016\/j.jtho.2018.08.276","article-title":"OA08.02 DREAM - A Phase 2 Trial of Durvalumab with First Line Chemotherapy in Mesothelioma: Final Result","volume":"13","author":"Nowak","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1136\/esmoopen-2019-000669_bb0120","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel","year":"2019","journal-title":"Lancet Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702920326193?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702920326193?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/esmoopen-2019-000669","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:22:59Z","timestamp":1761855779000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702920326193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":23,"alternative-id":["S2059702920326193"],"URL":"https:\/\/doi.org\/10.1136\/esmoopen-2019-000669","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How I treat malignant pleural mesothelioma","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/esmoopen-2019-000669","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 THE AUTHORS. Published by Elsevier Limited on behalf of European Society for Medical Oncology; Originally published by BMJ.","name":"copyright","label":"Copyright"}],"article-number":"e000669"}}